Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Nondepleting anti-CD154 (CD40 ligand) mAbs have proven effective in inducing transplantation tolerance in rodents and primates. In the induction phase, anti-CD154 Ab therapy is known to enhance apoptosis of Ag reactive T cells. However, this may not be the sole explanation for tolerance, as we show in this study that tolerance is maintained through a dominant regulatory mechanism which, like tolerance induced with CD4 Abs, manifests as infectious tolerance. Therefore, tolerance induced with anti-CD154 Abs involves not only the deletion of potentially aggressive T cells, but also a contagious spread of tolerance to new cohorts of graft-reactive T cells as they arise.


Journal article


J Immunol

Publication Date





4783 - 4786


Adoptive Transfer, Alemtuzumab, Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, CD40 Ligand, CD8-Positive T-Lymphocytes, Injections, Intraperitoneal, Injections, Intravenous, Lymphocyte Depletion, Lymphocyte Transfusion, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Skin Transplantation, T-Lymphocytes, Thymectomy, Transplantation Tolerance